We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Sustainability Goals

At Genentech, we apply the same science-based approach to environmental sustainability as we do to creating medicines for people with serious illnesses. As a healthcare company, it’s especially important for us to model the change required to improve the health of every person on the planet.

That’s why we have set ambitious sustainability goals to reduce our global environmental footprint by 50% by 2030 and to eliminate our Scope 1 and 2 emissions by 2050. In support of these goals, we are committed to achieving

  • 100% sustainable electricity for our South San Francisco campus by 2025
  • 75% reduction in Scope 1 and 2 emissions by 2029 (over 2019)
  • 100% fleet electrification of our sales and site vehicles by 2030

We track environmental impacts across all Genentech sites and we report our company-wide data and performance trends in our Sustainability Data and Trends Report. As we drive towards our 2030 goal to halve our environmental footprint, we are working towards interim 2025 milestones that will guide our progress for the South San Francisco campus.

Our Commitment to Environmental Sustainability